TY - JOUR
T1 - Gut gavage with antiendotoxin antibodies reduces the liberation of tumor necrosis factor-α after hemorrhage/resuscitation
AU - Gore, Dennis C.
AU - Sutherland, George
PY - 2000
Y1 - 2000
N2 - Objective: To evaluate the effect of gut gavage both alone and with enteral administration of monoclonal antibodies to endotoxin on the liberation of tumor necrosis factor (TNF)-α and subsequent hemodynamics after hemorrhage/resuscitation. Design: Dose response intervention, sham- controlled animal study. Setting: Research laboratory at a university medical center. Animals: Instrumented rats (250-325 g body weight) underwent standardized hemorrhage/resuscitation. Interventions: Animal groups received 4 hrs before hemorrhage/resuscitation: gastric gavage with Colyte alone (group 1), combined with E5 antiendotoxin at either 0.2 mg/100 g (group 2) or 2 mg/100 g body weight (group 3), or sham controls (group 4). There were six animals studied in each of the four groups. Measurements and Main Results: For animals receiving gut gavage and high-dose E5 antiendotoxin, plasma concentrations of TNF-α (pg/mL) at 120 mins after hemorrhage/resuscitation were significantly lower compared with sham controls (16 ± 4 group 3; 65 ± 36 group 4; mean ± SD, p < .05). At 300 mins, this same treatment group had a significantly higher mean blood pressure (mm Hg) (110 ± 6 group 3; 86 ± 7 group 4: p < .05). Also at 300 mins after hemorrhage/resuscitation, plasma lactate concentrations (mmol/L) were significantly lower for all gut gavage treatment groups compared with sham control animals (1.9 ± 0.2 group 1; 2.0 ± 0.2 group 2; 1.8 ± 0.2 group 3; 4.8 ± 2.8 group 4, p < .05). Conclusions: Prior treatment with gut gavage and enterally administered antiendotoxin antibodies reduces TNF-α liberation after hemorrhage/resuscitation and confers a subsequent improvement in hemodynamics and decreased plasma lactate concentrations. Such therapy may be efficacious in patients undergoing elective procedures where major hemorrhage is likely or in severely injured patients with continued or recurrent hemorrhage.
AB - Objective: To evaluate the effect of gut gavage both alone and with enteral administration of monoclonal antibodies to endotoxin on the liberation of tumor necrosis factor (TNF)-α and subsequent hemodynamics after hemorrhage/resuscitation. Design: Dose response intervention, sham- controlled animal study. Setting: Research laboratory at a university medical center. Animals: Instrumented rats (250-325 g body weight) underwent standardized hemorrhage/resuscitation. Interventions: Animal groups received 4 hrs before hemorrhage/resuscitation: gastric gavage with Colyte alone (group 1), combined with E5 antiendotoxin at either 0.2 mg/100 g (group 2) or 2 mg/100 g body weight (group 3), or sham controls (group 4). There were six animals studied in each of the four groups. Measurements and Main Results: For animals receiving gut gavage and high-dose E5 antiendotoxin, plasma concentrations of TNF-α (pg/mL) at 120 mins after hemorrhage/resuscitation were significantly lower compared with sham controls (16 ± 4 group 3; 65 ± 36 group 4; mean ± SD, p < .05). At 300 mins, this same treatment group had a significantly higher mean blood pressure (mm Hg) (110 ± 6 group 3; 86 ± 7 group 4: p < .05). Also at 300 mins after hemorrhage/resuscitation, plasma lactate concentrations (mmol/L) were significantly lower for all gut gavage treatment groups compared with sham control animals (1.9 ± 0.2 group 1; 2.0 ± 0.2 group 2; 1.8 ± 0.2 group 3; 4.8 ± 2.8 group 4, p < .05). Conclusions: Prior treatment with gut gavage and enterally administered antiendotoxin antibodies reduces TNF-α liberation after hemorrhage/resuscitation and confers a subsequent improvement in hemodynamics and decreased plasma lactate concentrations. Such therapy may be efficacious in patients undergoing elective procedures where major hemorrhage is likely or in severely injured patients with continued or recurrent hemorrhage.
KW - Cytokines
KW - Lactate
KW - Septic inflammatory response
UR - http://www.scopus.com/inward/record.url?scp=0033860437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033860437&partnerID=8YFLogxK
U2 - 10.1097/00003246-200007000-00039
DO - 10.1097/00003246-200007000-00039
M3 - Article
C2 - 10921574
AN - SCOPUS:0033860437
SN - 0090-3493
VL - 28
SP - 2425
EP - 2428
JO - Critical care medicine
JF - Critical care medicine
IS - 7
ER -